SEMA4 HOLDINGS CORP (SMFR)
US81663L1017 - Common Stock
SEMA4 HOLDINGS CORP
NASDAQ:SMFR (1/9/2023, 7:00:03 PM)
After market: 0.32 +0.01 (+3.03%)0.3106
+0.07 (+26.78%)
Company Profile
Sema4 Holdings Corp.is a patient centered health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,200 full-time employees. The company went IPO on 2020-09-04. The firm applies artificial intelligence and machine learning to clinical and genomic data to build models of human health and define individualized health trajectories. The Company’s health intelligence platform, Centrellis enables users to generate a complete understanding of disease and wellness and to provide science-driven solutions to pressing medical needs. Its Expanded Carrier Screen (ECS) is a carrier screen for inherited conditions. Its Noninvasive Prenatal Testing Solutions is a test that screens for autosomal and sex chromosome aneuploidies. Its Natalis Newborn Screening Solutions is a test of its screening portfolio allowing for detection of heritable conditions from pre-conception, pregnancy and childhood. The firm also includes Signal Precision Oncology Solutions.
Company Info
SEMA4 HOLDINGS CORP
333 Ludlow Street, North Tower, 8Th Floor
Stamford CONNECTICUT
P: 16177808742.0
CEO: Eli D. Casdin
Employees: 1200
Website: https://sema4.com/
SMFR News
San Diego, CA -- (SBWIRE) -- 02/08/2023 -- An investigation was announced for current long-term investors in shares of Sema4 Holdings Corp. (NASDAQ: SMFR) concerning potential breaches of fiduciary duties by certain directors of Sema4 Holdings Corp.
a year ago - Seeking AlphaSema4 changes name, issues guidance below consensus (NASDAQ:SMFR)Sema4 Holdings (SMFR) rose ~7% after the company said it has its changed name and ticker symbol and issued higher Y/Y 2022 revenue guidance.
a year ago - GeneDx Holdings Corp.Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
a year ago - Sema4Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceSema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation
Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation...
Data underscores the value of mitochondrial DNA testing and the opportunity to improve health outcomes for critically ill newborns with early medical...
SMFR Twits
Here you can normally see the latest stock twits on SMFR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
